aTyr Pharma Announces One-for-40 Reverse Stock Split

SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-40, effective at 5:00 p.m. ET on October 28, 2026.

aTyr’s common stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis commencing upon market open on October 29, 2026 under aTyr’s existing trading symbol “ATYR” with a new CUSIP number, 002120301. The reverse stock split was approved by aTyr’s stockholders at aTyr’s Special Meeting of Stockholders held on October 16, 2026, with the final ratio subsequently determined by aTyr’s Board of Directors. The reverse stock split is intended to bring aTyr into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.